DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)?
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- serum levels of soluble TWEAK
研究概览
简要总结
TWEAK (TNF weakly inducer of apoptosis) is a type II-transmembrane protein, member of the TNF ligand superfamily that can be cleaved to function as a soluble cytokine. Depending on target cell type, TWEAK triggers multiple cellular responses ranging from modulation of inflammation to cell death when it binds to its main receptor, Fn 14. Our team has been the first to describe pro-inflammatory effects of TWEAK during central nervous system inflammation. Various data support the possibility that TWEAK produced by synovial macrophages may contribute to chronic synovitis in animal models and in humans. In psoriatic arthritis (PsoA), anti-TNF therapy has been successful concording with the key role of TNF in the pathogenesis of this disease and the generation by psoriatic patients of neutralizing anti-TNF autoantibodies referred as "beneficial autoimmunity to pro-inflammatory mediators". In 2010, Van Kuijk et al. have described a high expression of TWEAK in the inflammatory synovial of PsoA and rheumatoid arthritis (RA) patients before and after anti-TNF therapy. The role of TNF-alpha in the regulation of TWEAK expression remains unclear.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •· Group RhPso :
- •Fill(Perform) the criteria CASPAR of the Rheumatism psoriasic (Taylor W, on 2006)
- •rheumatoid Absence of factor and antibody anti-CCP(anti-post office account) (cyclic citrulline peptide) in the serum
- •Indication established to begin a treatment with etanercept
- •Fill(Perform) the criteria of the ACR (American College of Rheumatology) for PR (revised in 1987) (Arneth FC, on 1988)
- •Presence of antibody anti-CCP(anti-post office account) in the serum
- •Indication established to begin a treatment with etanercept
排除标准
- •Minors(Miners)
- •pregnant or breast-feeding Women
- •Adults under guardianship
- •Nobody staying in a sanitary or social establishment
- •Persons in emergency situation and/or not beneficiaries of a national insurance scheme
- •Private persons of freedom
- •Arthritis or not labelled polyarthritis
- •Contraindication established in the treatment(processing) by etanercept
- •PUVAthérapie or cyclosporine or high dose of corticosteroid therapy (except intra-articular infiltration) or other anti-TNF treatment(processing) in two months preceding the inclusion
研究组 & 干预措施
patients PSORIATIC ARTHRITIS
etanercept Treatment
干预措施: etanercept Treatment (Drug)
patients RHEUMATOID ARTHRITIS
etanercept Treatment
干预措施: etanercept Treatment (Drug)
结局指标
主要结局
serum levels of soluble TWEAK
时间窗: 42 months
samples blood before and after etanercept Treatment
次要结局
未报告次要终点